MY200985A - Peptides and Combination of Peptides Of Non-Canonical Origin for use in Immunotherapy Against Different Types Of Cancers - Google Patents

Peptides and Combination of Peptides Of Non-Canonical Origin for use in Immunotherapy Against Different Types Of Cancers

Info

Publication number
MY200985A
MY200985A MYPI2020005127A MYPI2020005127A MY200985A MY 200985 A MY200985 A MY 200985A MY PI2020005127 A MYPI2020005127 A MY PI2020005127A MY PI2020005127 A MYPI2020005127 A MY PI2020005127A MY 200985 A MY200985 A MY 200985A
Authority
MY
Malaysia
Prior art keywords
peptides
combination
present
cancers
different types
Prior art date
Application number
MYPI2020005127A
Other languages
English (en)
Inventor
Jens Fritsche
Oliver Schoor
Franziska Hoffgaard
Heiko Schuster
Daniel Kowalewski
Toni Weinschenk
Chih-Chiang Tsou
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MY200985A publication Critical patent/MY200985A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2020005127A 2018-02-21 2019-02-08 Peptides and Combination of Peptides Of Non-Canonical Origin for use in Immunotherapy Against Different Types Of Cancers MY200985A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633325P 2018-02-21 2018-02-21
DE102018103944 2018-02-21
DE102018107224.4A DE102018107224A1 (de) 2018-02-21 2018-03-27 Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Publications (1)

Publication Number Publication Date
MY200985A true MY200985A (en) 2024-01-27

Family

ID=67482070

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020005127A MY200985A (en) 2018-02-21 2019-02-08 Peptides and Combination of Peptides Of Non-Canonical Origin for use in Immunotherapy Against Different Types Of Cancers

Country Status (22)

Country Link
US (79) US10993962B2 (enExample)
EP (2) EP3755708A1 (enExample)
JP (4) JP7536642B2 (enExample)
KR (2) KR20200116527A (enExample)
CN (1) CN114040921A (enExample)
AU (5) AU2019225879B2 (enExample)
BR (2) BR112020014272A2 (enExample)
CA (1) CA3086916A1 (enExample)
CL (4) CL2020002123A1 (enExample)
CO (1) CO2020009869A2 (enExample)
CR (1) CR20200365A (enExample)
DE (1) DE102018107224A1 (enExample)
EA (2) EA202091754A1 (enExample)
IL (2) IL276845A (enExample)
MA (1) MA51890A (enExample)
MX (2) MX2020007767A (enExample)
MY (1) MY200985A (enExample)
PE (2) PE20210376A1 (enExample)
PH (1) PH12020551295A1 (enExample)
SG (2) SG11202006630RA (enExample)
TW (3) TWI837747B (enExample)
WO (1) WO2019162110A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
CN114555809A (zh) * 2019-08-28 2022-05-27 森迪生物科学公司 组合癌症免疫疗法
KR20230088435A (ko) * 2020-10-16 2023-06-19 애플 인크. 고주파 무선 통신 시스템에서 빠른 빔 추적을 위한 시스템 및 방법
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
WO2022147029A2 (en) 2020-12-31 2022-07-07 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
JP2024535853A (ja) * 2021-09-17 2024-10-02 ウニヴェルシテ ド モントリオール 結腸直腸がんに対する新規の腫瘍特異的抗原及びそれらの使用
US20250147046A1 (en) 2022-01-25 2025-05-08 Ervimmune New method for identifying herv-derived epitopes
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025211983A1 (ru) * 2024-04-05 2025-10-09 Общество с ограниченной ответственностью "Альбоген" Пептиды с противоопухолевой активностью

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IN151589B (enExample) 1978-12-22 1983-05-28 Biogen Nv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US5759812A (en) * 1996-11-15 1998-06-02 Incyte Pharmaceuticals, Inc. Human selenium-binding protein
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU6027399A (en) 1998-09-04 2000-03-27 Ludwig Institute For Cancer Research An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
EP1001022A1 (en) 1998-10-16 2000-05-17 Boehringer Ingelheim International GmbH CAMEL, an alternative translation product of the tumour antigen LAGE-1
DE60029230T2 (de) * 1999-09-10 2007-06-06 The University Of Sydney, Sydney Dipeptidyl-peptidasen
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20030144474A1 (en) 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
PT1558643E (pt) 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
PL1760088T3 (pl) 2005-09-05 2008-10-31 Immatics Biotechnologies Gmbh Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
WO2014096399A1 (en) 2012-12-21 2014-06-26 Technische Universität Dresden Manipulation of hairy and split 3 (hes3) and its regulators/mediators as a new anti-cancer strategy
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI819228B (zh) 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201520579D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
SG11201808629UA (en) 2016-04-21 2018-11-29 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
FR3070845B1 (fr) 2017-09-13 2021-07-30 Oreal Outil de mesure d'au moins une propriete d'une surface corporelle et procede de mesure associe
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten

Also Published As

Publication number Publication date
US20210330708A1 (en) 2021-10-28
US20200306308A1 (en) 2020-10-01
US20230241115A1 (en) 2023-08-03
US20200323915A1 (en) 2020-10-15
US20230233612A1 (en) 2023-07-27
CL2021000841A1 (es) 2021-09-03
US20200323909A1 (en) 2020-10-15
US10772915B2 (en) 2020-09-15
CO2020009869A2 (es) 2020-08-21
DE102018107224A1 (de) 2019-08-22
AU2022202512B2 (en) 2023-12-14
US20230285462A1 (en) 2023-09-14
US11013766B2 (en) 2021-05-25
US10799537B2 (en) 2020-10-13
US10751369B2 (en) 2020-08-25
US20200323911A1 (en) 2020-10-15
US20200323913A1 (en) 2020-10-15
BR122020014377A8 (pt) 2023-03-28
US10874696B2 (en) 2020-12-29
US20230241109A1 (en) 2023-08-03
US20230241113A1 (en) 2023-08-03
US20200261505A1 (en) 2020-08-20
US20200323918A1 (en) 2020-10-15
AU2022202522B2 (en) 2023-12-21
US10792308B2 (en) 2020-10-06
US10869893B2 (en) 2020-12-22
US20200261504A1 (en) 2020-08-20
US20200297771A1 (en) 2020-09-24
AU2019225879B2 (en) 2022-01-27
CA3086916A1 (en) 2019-08-29
US10695373B2 (en) 2020-06-30
US10898519B2 (en) 2021-01-26
AU2022202520A1 (en) 2022-05-12
JP2025000689A (ja) 2025-01-07
US11918607B2 (en) 2024-03-05
US10869891B2 (en) 2020-12-22
US20200197441A1 (en) 2020-06-25
US20200360433A1 (en) 2020-11-19
US11058727B2 (en) 2021-07-13
US10888586B2 (en) 2021-01-12
US20200323907A1 (en) 2020-10-15
JP7536642B2 (ja) 2024-08-20
US20190255110A1 (en) 2019-08-22
PH12020551295A1 (en) 2021-07-12
US20200268799A1 (en) 2020-08-27
US20210113619A1 (en) 2021-04-22
CL2020002123A1 (es) 2020-10-16
US20200155605A1 (en) 2020-05-21
US20230263830A1 (en) 2023-08-24
US20200171091A1 (en) 2020-06-04
US11065279B2 (en) 2021-07-20
US20230241108A1 (en) 2023-08-03
US20210338734A1 (en) 2021-11-04
JP7732024B2 (ja) 2025-09-01
US20210260120A1 (en) 2021-08-26
TW201936630A (zh) 2019-09-16
US10709736B2 (en) 2020-07-14
US11020433B2 (en) 2021-06-01
US11179418B2 (en) 2021-11-23
US20200297772A1 (en) 2020-09-24
US20200038447A1 (en) 2020-02-06
US10780122B2 (en) 2020-09-22
EA202091833A1 (ru) 2020-11-25
MA51890A (fr) 2020-12-30
EA202091754A1 (ru) 2021-02-08
MX2020007808A (es) 2020-10-05
US10695375B2 (en) 2020-06-30
US11357797B2 (en) 2022-06-14
US20210060078A1 (en) 2021-03-04
EP4321529A2 (en) 2024-02-14
US10869894B2 (en) 2020-12-22
AU2020204568A1 (en) 2020-07-30
US20200038448A1 (en) 2020-02-06
US20210145887A1 (en) 2021-05-20
US20210213064A1 (en) 2021-07-15
US10695376B2 (en) 2020-06-30
US20200323916A1 (en) 2020-10-15
US10869896B2 (en) 2020-12-22
US20190255113A1 (en) 2019-08-22
US20200222465A1 (en) 2020-07-16
US10869890B2 (en) 2020-12-22
CL2020002387A1 (es) 2021-02-12
US20200206268A1 (en) 2020-07-02
US10888583B2 (en) 2021-01-12
US11033585B2 (en) 2021-06-15
US11779606B2 (en) 2023-10-10
US20210137986A1 (en) 2021-05-13
US11052114B2 (en) 2021-07-06
US11197892B2 (en) 2021-12-14
US20200179454A1 (en) 2020-06-11
US10869895B2 (en) 2020-12-22
US20200268800A1 (en) 2020-08-27
WO2019162110A1 (en) 2019-08-29
US11147838B2 (en) 2021-10-19
US20230241110A1 (en) 2023-08-03
US20210338735A1 (en) 2021-11-04
US20210401892A1 (en) 2021-12-30
IL276987A (en) 2020-10-29
TWI776160B (zh) 2022-09-01
US11052113B2 (en) 2021-07-06
US10888585B2 (en) 2021-01-12
US10780123B2 (en) 2020-09-22
US10888582B2 (en) 2021-01-12
US10905720B2 (en) 2021-02-02
US11020434B2 (en) 2021-06-01
US10869892B2 (en) 2020-12-22
EP4321529A3 (en) 2024-07-17
US20200038446A1 (en) 2020-02-06
MX2020007767A (es) 2020-10-12
US10905719B2 (en) 2021-02-02
US11147839B2 (en) 2021-10-19
US20210052653A1 (en) 2021-02-25
IL276845A (en) 2020-10-29
US10780124B2 (en) 2020-09-22
US10898518B2 (en) 2021-01-26
US20210060074A1 (en) 2021-03-04
US20210052651A1 (en) 2021-02-25
US10792307B2 (en) 2020-10-06
US20190255164A1 (en) 2019-08-22
JP2022050398A (ja) 2022-03-30
US20200085874A1 (en) 2020-03-19
US20200163996A1 (en) 2020-05-28
US20210244765A1 (en) 2021-08-12
US11103535B2 (en) 2021-08-31
US20200306311A1 (en) 2020-10-01
US11951132B2 (en) 2024-04-09
US10702553B2 (en) 2020-07-07
US10709738B2 (en) 2020-07-14
US20210052652A1 (en) 2021-02-25
JP2024099580A (ja) 2024-07-25
AU2020204568B2 (en) 2022-02-03
US20230241112A1 (en) 2023-08-03
US20220000922A1 (en) 2022-01-06
CR20200365A (es) 2020-09-18
TW202246307A (zh) 2022-12-01
US20200268798A1 (en) 2020-08-27
US11033583B2 (en) 2021-06-15
US11077142B2 (en) 2021-08-03
CN114040921A (zh) 2022-02-11
US20200093862A1 (en) 2020-03-26
AU2022202512A1 (en) 2022-05-12
US20230285461A1 (en) 2023-09-14
US11154576B2 (en) 2021-10-26
JP2021514178A (ja) 2021-06-10
US11040069B2 (en) 2021-06-22
US20200323910A1 (en) 2020-10-15
US20200155604A1 (en) 2020-05-21
US20230285460A1 (en) 2023-09-14
US10993962B2 (en) 2021-05-04
US11801264B2 (en) 2023-10-31
US20210145888A1 (en) 2021-05-20
US20200297770A1 (en) 2020-09-24
US20200085873A1 (en) 2020-03-19
US11026977B2 (en) 2021-06-08
US11013769B2 (en) 2021-05-25
US10888584B2 (en) 2021-01-12
US20200323914A1 (en) 2020-10-15
TWI837747B (zh) 2024-04-01
US20210069251A1 (en) 2021-03-11
TW202043257A (zh) 2020-12-01
KR20200123134A (ko) 2020-10-28
SG11202006630RA (en) 2020-09-29
BR112020014272A2 (pt) 2020-12-15
US11013768B2 (en) 2021-05-25
US20210137985A1 (en) 2021-05-13
EP3755708A1 (en) 2020-12-30
US20210145886A1 (en) 2021-05-20
US10813953B2 (en) 2020-10-27
US20210100845A1 (en) 2021-04-08
US20200108097A1 (en) 2020-04-09
US20200323919A1 (en) 2020-10-15
US10894064B2 (en) 2021-01-19
US20200261506A1 (en) 2020-08-20
US10874695B2 (en) 2020-12-29
CL2021000842A1 (es) 2021-09-03
US10695374B2 (en) 2020-06-30
AU2019225879A1 (en) 2020-07-09
US10695377B2 (en) 2020-06-30
US20190255112A1 (en) 2019-08-22
US10993964B2 (en) 2021-05-04
US11141437B2 (en) 2021-10-12
SG10202010171VA (en) 2020-11-27
US20200306305A1 (en) 2020-10-01
US11376281B2 (en) 2022-07-05
KR20200116527A (ko) 2020-10-12
US10709737B2 (en) 2020-07-14
US20200323906A1 (en) 2020-10-15
PE20211300A1 (es) 2021-07-20
PE20210376A1 (es) 2021-03-02
US11369636B2 (en) 2022-06-28
US20210060077A1 (en) 2021-03-04
BR122020014377A2 (pt) 2020-12-29
US20230241114A1 (en) 2023-08-03
US20200179453A1 (en) 2020-06-11
AU2022202522A1 (en) 2022-05-12
US20210052654A1 (en) 2021-02-25
JP7384884B2 (ja) 2023-11-21

Similar Documents

Publication Publication Date Title
PH12020551295A1 (en) Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
PH12018501828A1 (en) Uterine cancer treatments
WO2018189152A3 (en) Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
PH12019501377A1 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3875467A3 (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
PH12019502308A1 (en) Peptides and combination thereof for use in the immunotherapy against cancers
MY202812A (en) Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10201806839PA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
PH12021550205A1 (en) Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods
PH12021550346A1 (en) B*44 restricted peptides for use in immunotherapy against cancers and related methods
MX2018014316A (es) Nuevos peptidos y nueva combinacion de peptidos como dianas y para el uso en la inmunoterapia contra el cancer de vesicula biliar y el colangiocarcinoma, asi como otros tipos de cancer.
MX2021001622A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
PH12021550581A1 (en) Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods
PH12019502300A1 (en) Peptides and combination of peptides for use in immunotheraphy against leukemias and other cancers
PH12020551958A1 (en) Peptides for use in immunotherapy against cancers
PH12018502159A1 (en) Immunotheraphy against melanoma and other cancers
PH12020552013A1 (en) A*03 restricted peptides for use in immunotherapy against cancers and related methods
MY196837A (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
PH12021551460A1 (en) Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
PH12018502108A1 (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
PH12018502315A1 (en) Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
PH12018501639A1 (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
MY197679A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
MY197301A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
MY197794A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers